基于多层次新兴生物标志物的初级甲状腺功能过强症的精确分层治疗
Xi Zhu1, Qi Zhang2, Linghui Wang1,3
1Department of Head and Neck Surgery, the Fifth Hospital Affiliated to Wenzhou Medical University, Lishui Central Hospital, Lishui, Zhejiang, China.
Frontiers in endocrinology
|November 10, 2025
概括
精准医学通过使用多层次生物标志物来进行个性化风险分层和治疗,为原发性甲状腺功能障碍症 (PHPT) 提供了新的希望. 需要进一步的研究来标准化验证,并将这些先进的方法纳入临床实践.
科学领域:
- 内分泌学 在内分泌学.
- 生物标志物发现发现
- 精准医学是一门精准的医学.
背景情况:
- 初级甲状腺功能障碍症 (PHPT) 管理传统上依赖于生化特征和症状,但在检测亚临床损伤和预测进展方面存在局限性.
- 传统的策略需要更先进的,生物标志物驱动的方法,以获得有效的PHPT护理.
- 新兴技术如多omics,功能成像和AI正在为PHPT的精密医学铺平道路.
研究的目的:
- 审查多层次生物标志物的作用,以完善PHPT的风险分层.
- 探索这些生物标志物如何在PHPT中指导个性化治疗策略.
- 提出一个完整的框架,在PHPT管理中实施精准医学.
主要方法:
- 在PHPT中对遗传,表观遗传,非编码RNA,代谢和成像生物标记物的证据进行系统审查.
- 在PHPT中综合应用多omics和功能成像的数据.
- 开发一个建议的框架,将生物标志物分析和基于多学科团队 (MDT) 的决策结合起来.
主要成果:
- 多层次生物标志物在增强风险分层和个性化PHPT治疗方面表现有前途.
- 结合动态生物标志物分析和MDT输入的综合框架可以指导个性化的PHPT干预.
- 目前面临的挑战包括缺乏标准化生物标志物验证和用于临床翻译的综合分析平台.
结论:
- 由多层生物标志物驱动的精准医学,代表了PHPT管理的重大进步.
- 标准化验证和综合平台对于这些生物标志物的临床转化至关重要.
- 未来的合作努力和大规模研究对于在PHPT中建立基于证据的准确医学指南至关重要.
相关概念视频
00:59The Parathyroid Glands
4.3K
The two pairs of parathyroid glands embedded within the posterior surface of the thyroid gland are restricted by a dense capsule around them. These glands comprise two distinct cell populations—parathyroid oxyphil and parathyroid principal cells- pivotal in calcium homeostasis.
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
4.3K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
421
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
421